These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10394110)

  • 1. Suppressed activities of cathepsins and metalloproteinases in the chronic model of puromycin aminonucleoside nephrosis.
    Huang S; Schaefer RM; Reisch S; Paczek L; Schaefer L; Teschner M; Sebekova K; Heidland A
    Kidney Blood Press Res; 1999; 22(3):121-7. PubMed ID: 10394110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin B and L in nephron segments of rats with puromycin aminonucleoside nephrosis.
    Olbricht CJ; Cannon JK; Tisher CC
    Kidney Int; 1987 Sep; 32(3):354-61. PubMed ID: 3669494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered expression of NDST-1 messenger RNA in puromycin aminonucleoside nephrosis.
    Nakayama K; Natori Y; Sato T; Kimura T; Sugiura A; Sato H; Saito T; Ito S; Natori Y
    J Lab Clin Med; 2004 Feb; 143(2):106-14. PubMed ID: 14966466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis.
    Ebihara I; Nakamura T; Tomino Y; Koide H
    Nephrol Dial Transplant; 1997 May; 12(5):1001-6. PubMed ID: 9175058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats.
    Jones CL; Buch S; Post M; McCulloch L; Liu E; Eddy AA
    Am J Pathol; 1992 Dec; 141(6):1381-96. PubMed ID: 1281619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of lysosomal enzymes in isolated glomeruli. Alterations in experimental nephrosis.
    Velosa JA; Shah SV; Ou SL; Abboud HE; Dousa TP
    Lab Invest; 1981 Dec; 45(6):522-6. PubMed ID: 7321525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a low-protein diet on expression of non-muscle type myosin heavy-chain isoforms in glomeruli of rats with puromycin aminonucleoside nephrosis.
    Koide H; Nakamura T; Kimura K; Ebihara I; Nagai R; Tomino Y
    Nephrol Dial Transplant; 1996 Sep; 11(9):1769-74. PubMed ID: 8918620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside.
    Grond J; Weening JJ; Elema JD
    Lab Invest; 1984 Sep; 51(3):277-85. PubMed ID: 6471809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimentally induced puromycine aminonucleoside nephrosis (PAN) in rats: evaluation of angiogenic protein platelet-derived endothelial cell growth factor (PD-ECGF) expression in glomeruli.
    Seckin I; Uzunalan M; Pekpak M; Kokturk S; Sonmez H; Oztürk Z; Demirci S; Yaprak E
    J Biomed Sci; 2012 Feb; 19(1):24. PubMed ID: 22335899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis.
    Jones CL; Buch S; Post M; McCulloch L; Liu E; Eddy AA
    Kidney Int; 1991 Dec; 40(6):1020-31. PubMed ID: 1762303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in puromycin aminonucleoside nephrosis in two rat strains.
    Grond J; Muller EW; van Goor H; Weening JJ; Elema JD
    Kidney Int; 1988 Feb; 33(2):524-9. PubMed ID: 3361753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cyclosporin on podocyte ZO-1 expression in puromycin aminonucleoside nephrosis rats.
    Kim BS; Park HC; Kang SW; Choi KH; Ha SK; Han DS; Lee HY
    Yonsei Med J; 2005 Feb; 46(1):141-8. PubMed ID: 15744817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ameliorative effects of dietary protein restriction in chronic aminonucleoside nephrosis.
    Diamond JR; Karnovsky MJ
    J Lab Clin Med; 1987 May; 109(5):538-44. PubMed ID: 3572200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective effect of the L/N-type calcium channel antagonist cilnidipine on puromycin aminonucleoside-induced nephrosis in rats.
    Takashima K; Nishiyama C; Arisaka N; Takahashi T; Souma S; Tsuda M; Hayashi M; Kasahara H; Kodama H; Tamura T; Murakami M; Kuroda J; Sato F
    Arzneimittelforschung; 2009; 59(2):79-85. PubMed ID: 19338138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caffeine augments proteinuria in puromycin-aminonucleoside nephrotic rats.
    Tofovic SP; Rominski BR; Bastacky S; Jackso EK; Kost CK
    Ren Fail; 2000 Mar; 22(2):159-79. PubMed ID: 10803761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein restriction influences glomerular matrix turnover and tubular hypertrophy by modulation of renal proteinase activities.
    Schaefer L; Meier K; Häfner C; Teschner M; Heidland A; Schaefer RM
    Miner Electrolyte Metab; 1996; 22(1-3):162-7. PubMed ID: 8676812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of CD54, CD18, MHC class II molecules, and proliferating cell nuclear antigen in acute puromycin aminonucleoside nephrosis.
    Fernandez L; Romero M; Rincón J; Mosquera J
    Nephron Exp Nephrol; 2003; 94(2):e55-65. PubMed ID: 12845231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal structural abnormalities following recovery from acute puromycin nephrosis.
    Rasch R; Nyengaard JR; Marcussen N; Meyer TW
    Kidney Int; 2002 Aug; 62(2):496-506. PubMed ID: 12110010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of captopril on chronic puromycin aminonucleoside nephrosis in rats.
    Radin MJ; Wilke WL; Fettman MJ
    Res Commun Chem Pathol Pharmacol; 1986 Nov; 54(2):279-82. PubMed ID: 3538253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoids as a potential treatment for experimental puromycin-induced nephrosis.
    Moreno-Manzano V; Mampaso F; Sepúlveda-Muñoz JC; Alique M; Chen S; Ziyadeh FN; Iglesias-de la Cruz MC; Rodríguez J; Nieto E; Orellana JM; Reyes P; Arribas I; Xu Q; Kitamura M; Lucio Cazana FJ
    Br J Pharmacol; 2003 Jun; 139(4):823-31. PubMed ID: 12813006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.